Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

The CAM-E ALG-001075 potently reduces HBV cccDNA in preclinical experiments

Friday, September 12, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the promising results of the CAM-E ALG-001075 in preclinical trials, demonstrating its ability to significantly reduce HBV cccDNA levels. This advancement could lead to improved treatment options for patients suffering from chronic HBV infection. The findings highlight the potential of ALG-001075 in addressing a critical need in hepatitis B management.
Price reaction · baseline $10.88 (2025-09-11 close) · hit pre-market · clean, no other ALGS news in the window
day 0 close
-6.3%
day 1
-13.9%
day 3 · peak
-15.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • The CAM-E ALG-001075 shows potent efficacy in reducing HBV cccDNA.
  • Preclinical experiments indicate promising results for chronic HBV treatment.
  • Potential for significant advancements in HBV infection management.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is CAM-E ALG-001075?

CAM-E ALG-001075 is a therapeutic candidate aimed at reducing HBV cccDNA.

What were the results of the preclinical experiments?

The preclinical experiments showed that CAM-E ALG-001075 potently reduces HBV cccDNA levels.

Why is reducing HBV cccDNA important?

Reducing HBV cccDNA is crucial for managing chronic HBV infections and improving patient outcomes.

What does this mean for chronic HBV treatment?

The findings suggest that CAM-E ALG-001075 could offer new treatment options for chronic HBV patients.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare HBV cccDNA preclinical trials chronic HBV
Last updated: Sep 12, 2025

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →